Annalisa Trama1, Roberto Foschi2, Nerea Larrañaga3, Milena Sant4, Rafael Fuentes-Raspall5, Diego Serraino6, Andrea Tavilla7, Liesbet Van Eycken8, Nicola Nicolai9. 1. Department of Preventive and Predictive Medicine, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. Electronic address: annalisa.trama@istitutotumori.mi.it. 2. Department of Preventive and Predictive Medicine, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. 3. Basque Cancer Registry, Public Health Division of Gipuzkoa, Basque Health Department, Spain and CIBER of Epidemiology and Public Health (CIBERESP), Avda de Navarra 4, Donostia-San Sebastian 20013, Gipuzkoa, Spain. 4. Department of Preventive and Predictive Medicine, Analytical Epidemiology and Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy. 5. Catalan Institute of Oncology, Avinguda França s/n, 17007 Girona, Spain. 6. SOC Epidemiologia e Biostatistica, IRCCS Centro di Riferimento Oncologico, Via Franco Gallini 2, 33081 Aviano (PN), Italy. 7. National Centre for Epidemiology, Surveillance and Health Promotion, Department of Cancer Epidemiology, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome, Italy. 8. Belgian Cancer Registry, rue Royale 215 BP 7, 1210 Bruxelles, Belgium. 9. Department of surgical urology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Abstract
BACKGROUND: We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. METHODS: The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000-2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999-2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. RESULTS: We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing age for all tumours considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for penile cancer patients did not improve from 1999 to 2007. Survival for testicular cancer patients remained stable at high levels since 1999. Survival for prostate cancer patients increased over time. CONCLUSIONS: Treatment standardisation and centralisation for very rare diseases such as penile cancers or advanced testicular tumours should be supported. The high survival of testicular cancer makes long-term monitoring of testicular cancer survivors necessary and CRs can be an important resource. Prostate cancer patients' survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for Prostate Cancer should continue to clarify the impact of screening on prostate cancer mortality together with population based studies including information on stage and treatments.
BACKGROUND: We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. METHODS: The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000-2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999-2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. RESULTS: We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing age for all tumours considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for penile cancerpatients did not improve from 1999 to 2007. Survival for testicular cancerpatients remained stable at high levels since 1999. Survival for prostate cancerpatients increased over time. CONCLUSIONS: Treatment standardisation and centralisation for very rare diseases such as penile cancers or advanced testicular tumours should be supported. The high survival of testicular cancer makes long-term monitoring of testicular cancer survivors necessary and CRs can be an important resource. Prostate cancerpatients' survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for Prostate Cancer should continue to clarify the impact of screening on prostate cancer mortality together with population based studies including information on stage and treatments.
Authors: M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez Journal: Clin Transl Oncol Date: 2017-07-17 Impact factor: 3.405
Authors: Antonella Zucchetto; Andrea Gini; Nitin Shivappa; James R Hébert; Carmen Stocco; Luigino Dal Maso; Silvia Birri; Diego Serraino; Jerry Polesel Journal: Int J Cancer Date: 2016-06-11 Impact factor: 7.396
Authors: Wen-Jung Chen; Cheng-Yu Huang; Yu-Hui Huang; Shao-Chuan Wang; Tzuo-Yi Hsieh; Sung-Lang Chen; Wen-Wei Sung; Tsung-Hsien Lee Journal: Int J Environ Res Public Health Date: 2019-12-23 Impact factor: 3.390
Authors: Martin H Umbehr; Lucas M Bachmann; Cedric Poyet; Peter Hammerer; Johann Steurer; Milo A Puhan; Anja Frei Journal: Health Qual Life Outcomes Date: 2018-02-20 Impact factor: 3.186